8-K: Actuate Therapeutics Secures $100M ATM Equity Facility

Actuate Therapeutics, Inc. has entered into an At-the-Market sales agreement to potentially raise up to $100 million through the sale of common stock.

Summary

• Actuate Therapeutics, Inc. entered into an At the Market Issuance Sales Agreement (ATM Agreement) on November 28, 2025, with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC.
• The ATM Agreement allows the company to offer and sell, from time to time at its sole discretion, shares of its common stock with an aggregate offering price of up to $100,000,000.
• Sales of common stock will be made through the sales agents as an at-the-market offering, as defined in Rule 415(a)(4) under the Securities Act of 1933, including privately negotiated and block transactions.
• The company will pay the sales agents a commission of up to 3.0% of the gross sales proceeds of any common stock sold under the Agreement.
• The offering will be made under the company's effective Registration Statement on Form S-3 (File No. 333-289988), filed on September 2, 2025, and a prospectus supplement filed on November 28, 2025.
• The company is an "emerging growth company" and its common stock is registered on The Nasdaq Stock Market LLC under the trading symbol ACTU.
• As of October 9, 2025, the aggregate market value of the company's non-affiliate common equity was approximately $77.5 million, meeting the requirements of General Instruction I.B.1 of Form S-3.

Sentiment

Score: 6

Explanation: The establishment of an At-the-Market equity facility provides Actuate Therapeutics with flexible access to capital, which is positive for funding ongoing operations and development. However, it also implies continued capital requirements and the potential for future shareholder dilution.

Positives

• Provides flexible access to capital, allowing the company to raise up to $100 million opportunistically based on market conditions and capital needs.
• Utilizes an existing effective Registration Statement on Form S-3, indicating readiness and efficiency for capital market access.
• The company meets the S-3 eligibility requirements for primary offerings, providing broader access to capital markets.

Negatives

• Potential for significant shareholder dilution as up to $100 million in new common stock may be issued.
• Commissions of up to 3.0% of gross sales proceeds will reduce the net capital raised by the company.
• The need for an At-the-Market facility indicates ongoing capital requirements, likely for funding research, development, and general corporate purposes.

Risks

• Shareholder dilution from the issuance of new common stock, which could negatively impact earnings per share and stock price.
• The actual amount of capital raised is uncertain and dependent on market conditions, the company's stock price, and the sales agents' ability to sell shares.
• Market price volatility could impact the effectiveness and timing of capital raises, potentially forcing sales at unfavorable prices.
• The company's ability to maintain its S-3 eligibility for primary offerings (requiring a public float of at least $75 million) could be impacted by future stock price declines or changes in affiliate ownership, potentially limiting future financing options.
• Restrictions prevent the simultaneous use of this At-the-Market facility and the existing Committed Equity Facility on the same trading day, which could limit financing flexibility.

Future Outlook

The At-the-Market facility provides a mechanism for future capital raises, offering financial flexibility to fund ongoing operations and development. The timing and amount of future sales will be at the company's discretion, based on market conditions and capital needs.

Industry Context

This At-the-Market (ATM) offering is a common financing strategy for biotechnology and pharmaceutical companies, particularly those classified as 'emerging growth companies,' which often require substantial and flexible capital to fund extensive research and development, clinical trials, and general corporate purposes. ATMs allow companies to raise capital incrementally without the upfront costs and rigid timing associated with traditional underwritten offerings, aligning with the unpredictable nature of drug development timelines.

Comparison to Industry Standards

• The use of an At-the-Market facility is a standard and flexible capital raising tool for publicly traded companies, especially those in the biotech sector, to manage ongoing funding needs.
• The commission rate of up to 3.0% for the sales agents is within the typical range for ATM agreements in the industry.
• Actuate Therapeutics' public float of approximately $77.5 million as of October 9, 2025, places it just above the $75 million threshold required for primary offerings under General Instruction I.B.1 of Form S-3, a key regulatory benchmark for efficient access to capital markets.

Related Party Transactions

• The company has an existing Committed Equity Facility (CEF) with B. Riley Principal Capital II, LLC (BRPC II), an affiliate of B. Riley Securities, Inc., one of the sales agents for the ATM facility.
• B. Riley Securities, Inc. will also act as an executing broker for resales of common stock purchased by BRPC II under the Committed Equity Facility.
• Specific restrictions are in place to prevent the company from using both the ATM facility and the CEF on the same trading day.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new common stock, which could impact per-share metrics. However, the capital raised supports the company's operations and development, potentially enhancing long-term value.
• Company Operations: Provides enhanced liquidity and financial flexibility to fund ongoing research, development, and general corporate purposes, supporting the advancement of its pipeline.

Next Steps

• The company may, from time to time, offer and sell shares of common stock through the sales agents based on its discretion and market conditions.
• The sales agents will use commercially reasonable efforts to sell common stock according to the company's instructions.
• The company will file prospectus supplements with the SEC to report the amount of Placement Shares sold, net proceeds, and compensation paid to agents.

Key Dates

Recommendation

The At-the-Market facility provides crucial financial flexibility for Actuate Therapeutics, an emerging growth company, to fund its operations and development pipeline. While this access to capital is positive for the company's stability and strategic execution, the potential for significant shareholder dilution from the issuance of up to $100 million in common stock warrants a 'hold' recommendation. Investors should monitor the pace and pricing of share issuances, as well as the company's progress in its clinical programs, to assess the long-term value creation against the dilutive effects.

Keywords

Actuate Therapeutics, ATM, At-the-Market, Equity Offering, Capital Raise, Common Stock, Dilution, SEC Filing, Form 8-K, ACTU, B. Riley Securities, Craig-Hallum Capital Group